Goldman Sachs Group set a €92.00 ($106.98) price target on Merck KGaA (FRA:MRK) in a research note issued to investors on Tuesday. The brokerage currently has a neutral rating on the healthcare company’s stock.
A number of other analysts have also commented on the company. Sanford C. Bernstein set a €105.00 ($122.09) price objective on Merck KGaA and gave the company a buy rating in a research note on Tuesday, July 3rd. Berenberg Bank set a €104.00 ($120.93) price objective on Merck KGaA and gave the company a buy rating in a research note on Wednesday, July 4th. Societe Generale set a €88.00 ($102.33) price objective on Merck KGaA and gave the company a neutral rating in a research note on Wednesday, July 4th. DZ Bank reaffirmed a neutral rating on shares of Merck KGaA in a research note on Thursday, August 16th. Finally, Warburg Research set a €105.00 ($122.09) price objective on Merck KGaA and gave the company a buy rating in a research note on Tuesday, July 3rd. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of €98.71 ($114.78).
MRK stock opened at €87.68 ($101.95) on Tuesday. Merck KGaA has a 52 week low of €76.60 ($89.07) and a 52 week high of €115.00 ($133.72).
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Recommended Story: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.